KHK 7580

Drug Profile

KHK 7580

Alternative Names: KHK-7580; MT-4580

Latest Information Update: 30 Mar 2017

Price : $50

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Kyowa Hakko Kirin
  • Class Antithyroids; Small molecules
  • Mechanism of Action Calcium-sensing receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Secondary hyperparathyroidism

Most Recent Events

  • 01 Mar 2017 Kyowa Hakko Kirin completes a phase III trial for Secondary hyperparathyroidism in Japan (JapicCTI153013)
  • 23 Sep 2015 Kyowa Hakko Kirin plans a phase II/III trial for Secondary hyperparathyroidism (In patients receiving haemodialysis) in Japan (PO) (NCT02549391)
  • 19 Sep 2015 Kyowa Hakko Kirin plans a phase III trial for Secondary hyperparathyroidism (In patients receiving haemodialysis) in Japan (NCT02549404)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top